On Wednesday, Jarden Corp (NYSE:JAH)’s shares inclined 1.34% to $53.79.
With spring produce filling farmers markets, home gardens and CSA shares nationwide, many are interested in learning how to savor the fresh flavors of the season. Jarden Corp (NYSE:JAH), leaders in advancing the art of home canning and makers of Ball brand home canning products, declared the release of the 37th Edition of the Ball Blue Book® Guide to Preserving providing safe ways to start fresh preserving. The most trusted resource in home canning for over 100 years, the 2015 release of the Ball Blue Book is its largest update since the first edition in 1909. Expanding 56% from the previous edition, the 37th edition of the Ball Blue Book comprises 75 new recipes, pictorial step by step guides for starters, a special section for Meal Creations and unique “You Choose” and “Our Tip” recommendations where creative variations and assistful techniques are listed for creating your own signature foods.
Jarden Corporation manufactures, markets, and distributes consumer products worldwide. The company’s Outdoor Solutions segment offers camping and outdoor equipment; fishing and team sports equipment; alpine and nordic skiing, snowboarding, snowshoeing, and in-line skating products; technical and outdoor apparel and equipment; personal flotation devices, water sports equipment, and all-terrain vehicle gears; and inflatable air beds and accessories.
CBL & Associates Properties, Inc. (NYSE:CBL)’s shares dropped -0.85% to $17.56.
CBL & Associates Properties, Inc. (CBL) declared that it will provide an online audio simulcast of the presentation given by its President and Chief Executive Officer, Stephen D. Lebovitz, to the investment community at REITWeek 2015: NAREIT’s Investor Forum in New York City. The presentation will take place on Tuesday, June 9, 2015, at 8:45 a.m. Eastern Time.
CBL & Associates Properties, Inc. is a public real estate investment trust. It engages in acquisition, development, and administration of properties. The fund invests in the real estate markets of United States. Its portfolio comprises of enclosed malls and open-air centers. CBL & Associates Properties is based in Oak Brook, Illinois. CBL & Associates Properties was founded in 1978 and is based in Chattanooga, Tennessee with additional offices in Waltham, Massachusetts; Chesterfield, Missouri; and Irving, Texas.
At the end of Wednesday’s trade, Sanofi SA (ADR) (NYSE:SNY)‘s shares surged 2.76% to $51.15.
Genzyme, a Sanofi SA (ADR) (SNY) company, declared that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. This enzyme replacement therapy is being investigated for the treatment of patients with nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B, as opposed to type A which is characterized by neurological involvement. ASMD is a serious and life-threatening disorder caused by insufficient activity of the enzyme acid sphingomyelinase (ASM), which results in toxic accumulation of sphingomyelin. There are presently no approved treatment options for patients with Niemann-Pick disease type B.
Breakthrough Therapy designation is intended to expedite the development and review of investigational new drugs that target serious or life-threatening conditions. The criteria for granting Breakthrough Therapy designation are preliminary clinical evidence of substantial improvement on a clinically noteworthyendpoint over accessible therapies. The Breakthrough Therapy designation is distinct from the FDA’s other mechanisms to expedite drug development and review, and will allow for a close partnership between Genzyme and the FDA on the olipudase alfa development program.
Olipudase alfa is being developed by Genzyme to potentially address the fundamental defect underlying the disease. Supplementing the defective or deficient native enzyme with olipudase alfa allows for the breakdown of sphingomyelin, whose accumulation is responsible for the clinical manifestation of ASMD.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
ARRIS Group, Inc. (NASDAQ:ARRS), ended its Wednesday’s trading session with 1.99% gain, and closed at $33.84.
ARRIS Group, Inc. (ARRS) is celebrating this milestone at its office in San Diego, California—where the members of the design team pioneered the original system for digital TV. The esteemed members in attendance will comprise Dr. Jerry Heller, Dr. Woo Paik, Dr. Paul Moroney, Bob Rast, and Marc Tayer.
The San Diego team projected the first all-digital TV system to the FCC’s Advisory Committee on Advanced Television Service. This invention led to modern advances in TV—startning with digital satellite service in 1994, digital cable in 1996, and terrestrial over-the-air digital broadcasts, and ongoing with recently mobile and streaming Internet TV, DVR, 4K, and multiscreen experiences. Along the way, ARRIS has continued this pioneering legacy with innovations that have brought the future of TV to millions of consumers around the world.
ARRIS’s celebration on Monday brings five of the original team members together for a panel that will review their impact on digital broadcasting, digital cable, and modern television technology—together with a talk about of the future of TV.
ARRIS Group, Inc. provides media entertainment and data communications solutions in the United States and internationally. The company operates in two segments, Customer Premises Equipment and Network & Cloud. The Customer Premises Equipment segment offers various product solutions, counting set-top boxes, gateways, digital subscriber lines and cable modems, and embedded multimedia terminal adapters and voice/data modems that enable service providers to offer voice, video, and high-speed data services to residential and business subscribers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
